In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CV Therapeutics, Inc.

http://www.cvt.com

Latest From CV Therapeutics, Inc.

Russia-Ukraine War Likely To Claim Sputnik V Partners As Casualty

The first COVID-19 vaccine to be approved, Sputnik V, faced production issues soon after, but a solution was found with Sputnik Light. Now, data indicate manufacturing partners in India, China, Korea and other countries could be left holding unsold inventory earmarked for exports as high vaccination numbers will mean limited scope for domestic supplies

Commercial Coronavirus COVID-19

Intas And Axantia Ink Middle East Ranibizumab Distribution Deal

Intas has secured a distributor for its ranibizumab biosimilar throughout select countries in the Middle East, while Phase III trials continue ahead of anticipated US approval.

Deals Biosimilars

Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.

Clinical Trials Business Strategies

MeMed Secures $93M Financing To Commercialize Diagnostics Platform

The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.

Diagnostics Financing
See All

Company Information

UsernamePublicRestriction

Register